Stem Cell Therapeutics

Named companies include Beam Therapeutics, Sana Biotechnology and Regenerative Processing Plant LLC; FACTS lists 287 companies overall and 14 startups. Beam is developing base-edited autologous hematopoietic cell therapies. Sana is advancing pluripotent stem cell-derived programs, including manufacturing preparation for SC451. Regenerative Processing Plant works on regenerative-medicine products and platforms.

FACTS identifies Beam Therapeutics, Sana Biotechnology and Regenerative Processing Plant LLC among 14 startups, but does not rank them by promise. Beam’s work includes base-edited autologous hematopoietic stem-cell therapies. Sana is advancing SC451 toward a phase 1/2 trial. Regenerative Processing Plant’s work aligns with mesenchymal-cell-derived biologics and extracellular-vesicle approaches.

Harvard University has 1,131 recent-window documents, the U.S. National Institutes of Health has 1,546, and the University of Texas M. D. Anderson Cancer Center has 924 in FACTS. Their research spans mesenchymal and induced-pluripotent-cell approaches, hematopoietic transplantation, and transplant outcomes. Stanford University and Mayo Clinic are also prominent research organizations in the data.

FACTS records $820.5 million in grants across 855 awards since 2020, alongside $1.89 billion across 23 funding rounds. These are aggregated funding figures, not a measure of funding available to any specific company or program. The listed rounds include grants, spinouts and other financing types, so individual entries may not represent direct investment in a stem cell therapy.

The Regents of the University of California leads the listed patent holders with 31 patents, followed by Stanford University with 21 and Kyoto University with 20. Memorial Sloan Kettering Cancer Center and Regeneron Pharmaceuticals Inc each have 19 listed patents. These are holder counts in FACTS, not measures of patent quality or commercial value.

No: patent activity declined 49.6% in the last 12 months versus the previous 12 months, while publications grew 3.3%. FACTS lists 2,183 patents in its 24-month window. This divergence suggests that publication activity remains strong even as recent patent activity has contracted; it does not by itself indicate a change in clinical progress.

In February 2026, a Japanese specialist panel endorsed Sumitomo Pharma’s induced-pluripotent-stem-cell-derived Parkinson’s treatment, and July 2026 reporting described dopamine-cell transplantation as feasible while noting unresolved long-term safety and benefit. Recent research also examines allogeneic transplant conditioning, T-cell exhaustion and mesenchymal-cell approaches for stroke and diabetes.

FACTS identifies five approaches: hematopoietic transplantation, mesenchymal stromal cell therapies, pluripotent stem cell-derived cells, neural stem and progenitor cells, and tissue-specific adult stem cells. They differ in the cells used and their intended role, from rebuilding blood and immune systems to supporting tissue repair or replacing specific cell types. Each faces distinct manufacturing, safety or integration challenges.

The United States leads FACTS with 160,754 documents and a 40.2% share, followed by China with 93,639 and a 23.4% share. The United Kingdom follows with 44,897 documents and an 11.2% share. These figures describe the country distribution of documents, not a direct comparison of clinical maturity or commercial deployment.

FACTS includes applications in hematologic and immune disorders, neurologic disorders and injury, musculoskeletal repair, cardiovascular disease, ocular disease, and diabetes and metabolic disease. Hematologic and immune disorders account for 7,973 documents, while neurologic disorders and injury account for 4,278. These categories include research and patent activity and do not imply that therapies are established for every condition.